Plaque regression and improved clinical outcomes following statin treatment in atherosclerosis

Panminerva Medica

Volumn 54, Issue 2, 2012, Pages 71-81

  Girotra, S ^a   Murarka, S ^b   Migrino, R Q ^b  

^a BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^b Office of Research Phoenix Veterans Affairs Health Care System   (United States)

Author keywords

3 hydroxy; 3 rnethylglutaryl; Coenzyme a atherosclerosis; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ATHEROSCLEROSIS; CORONARY ANGIOGRAPHY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLAQUE, ATHEROSCLEROTIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84862515010     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (95)

1. Steinberg D. Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: Part I. J Lipid Res 2004;45:1583-93.
2. Lyon TP, Yankley A, Gofman JW, Strisower B. Lipoproteins and diet in coronary heart disease; a five-year study. Calif Med 1956;84:3258.
3. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease-six year follow-up experience. The framingham study. Ann Intern Med 1961;55:33-50.
4. Keys A. The diet and the development of coronary heart disease. J Chronic Dis 1956;4:364-80.
5. Tobert JA. Lovastatin and beyond: the history of the hmg-coa reductase inhibitors. Nat Rev Drug Discov 2003;2:517-26. (Pubitemid 37361744)
6. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997;336:1276-82. (Pubitemid 27187780)
7. Deguchi JO, Aikawa E, Libby P, Vachon JR, Inada M, Krane SM, Whittaker P, Aikawa M. Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation 2005; 112:2708-15. (Pubitemid 41532609)
8. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. Imgamma potentiates atherosclerosis in apoe knock-out mice. The Journal of Clinical Investigation 1997;99:2752-61. (Pubitemid 27259823)
9. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.
10. Little WC. Angiographic assessment of the culprit coronary artery lesion before acute myocardial infarction. Am J Cardiol 1990;66:44G-7G. (Pubitemid 20384284)
11. Muller JE, Toiler GH. Triggering and hourly variation of onset of arterial thrombosis. Ann Epidemiol 1992;2:393-405.
12. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J et al. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part I. Circulation 2003;108:1664-72. (Pubitemid 37243650)
13. Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol 2002;15:439-46. (Pubitemid 35387383)
14. Giroud D, Li JM, Urban P, Meier B, Rutishauer W. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 1992;69:729-32.
15. Hackett D, Davies G, Maseri A. Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. European Heart Journal 1988;9:1317-23. (Pubitemid 19043208)
16. Libby P, Sasiela W. Plaque stabilization: Can we turn theory into evidence? Am J Cardiol 2006;98:26P-33P.
17. MoiseA, Lesperance J, Theroux P, Taeymans Y, Goulet C, Bourassa MG. Clinical and angiographic predictors of new total coronary occlusion in coronary artery disease: Analysis of 313 nonoperated patients. Am J Cardiol 1984;54:1176-81. (Pubitemid 15220535)
18. Srivatsa SS, Edwards WD, Boos CM, Grill DE, Sangiorgi GM, Garratt KN et al. Histologic correlates of angiographic chronic total coronary artery occlusions: Influence of occlusion duration on neovascular channel patterns and intimai plaque composition. J Am Coll Cardiol 1997;29:955-63. (Pubitemid 27149567)
19. Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: An intravascular ultrasound study. Circulation 2000;101:598-603. (Pubitemid 30094729)
20. Varnava AM, Mills PG, Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability. Circulation 2002;105:939-43. (Pubitemid 34184571)
21. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. The American Journal of Medicine 2001;111:185-91. (Pubitemid 32786945)
22. Ma PT, Gil G, Sudhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mrna for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci U S A 1986;83:8370-4. (Pubitemid 17182502)
23. Reihner E, Rudling M, Stahlberg D, Berglund L, Ewerth S, Bjorkhem I, Einarsson K et al. Influence of pravastatin, a specific inhibitor of hmg-coa reductase, on hepatic metabolism of cholesterol. N Engl J Med 1990;323:224-8. (Pubitemid 20225042)
24. Arad Y, Ramakrishnan R, Ginsberg HN. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipemia: Evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 1992;41:487-93.
25. Influence of pravastatin and plasma lipids on clinical events in the west of Scotland coronary prevention study (woscops). Circulation 1998;97:1440-5.
26. Jarvisalo MJ, Toikka JO, Vasankari T, Mikkola J, Viikari JS, Hartiala JJ et al. Hmg coa reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 1999;147:237-42. (Pubitemid 29512254)
27. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110:285-8. (Pubitemid 34847957)
28. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by hmg coa reductase inhibitors. Circulation 1998;97:1129-35. (Pubitemid 28152885)
29. Li J, Li JJ, He JG, Nan JL, Guo YL, Xiong CM. Atorvastatin decreases c-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappab pathway. Cardiovascular Therapeutics 2010;28:8-14.
30. Vasa M, Fichtischerer S, Adler K, Aicher A, Martin H, Zeiher AM et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001;103:2885-90. (Pubitemid 32578123)
31. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T et al. Statin therapy accelerates reendothelialization: A novel effect involving mobilization and incorporation of bone marrowderived endothelial progenitor cells. Circulation 2002; 105:3017-24. (Pubitemid 34693836)
32. Abela GS. Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. J Clin Lipidol 2010;4:156-64.
33. Abela GS, Vedre A, Janoudi A, Huang R, Durga S, Tamhane U. Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization. Am J Cardiol 2011;107:1710-7.
34. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 1995;333:1301-7.
35. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of afcaps/ texcaps. Air force/texas coronary atherosclerosis prevention study. JAMA 1998;279:1615-22. (Pubitemid 28248586)
36. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4s). Lancet 1994;344:1383-9.
37. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001-9. (Pubitemid 26338729)
38. [No authors listed]. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic disease (lipid) study group. N Engl J Med 1998;339:1349-57.
39. Mrc/bhf heart protection study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
40. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (Ascot-lla): a multicentre randomised controlled trial. Lancet 2003;361:1149-58. (Pubitemid 36398384)
41. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM et al. Pravastatin in elderly individuals at risk of vascular disease (prosper): a randomised controlled trial. Lancet 2002;360:1623-30. (Pubitemid 35379733)
42. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 2008;359:2195-207.
43. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35. (Pubitemid 40471450)
44. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme 1 et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The ideal study: A randomized controlled trial. JAMA 2005;294:2437-45. (Pubitemid 41627921)
45. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The miraci study: A randomized controlled trial. JAMA 2001;285:1711-8. (Pubitemid 32259905)
46. Liem AH, van Boven AJ, Veeger NJ, Withagen AJ, Robles de Medina RM, Tijssen JG et al. Effect of fluvastatin on ischaemia following acute myocardial infarction: A randomized trial. Eur Heart J 2002;23:1931-7. (Pubitemid 35448551)
47. Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? Am J Cardiol 2006;98:18P-25P.
48. Thompson PL, Meredith I, Amerena J, Campbell TJ, Sloman JG, Harris PJ. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: The pravastatin in acute coronary treatment (pact) trial. Am Heart J 2004; 148:e2.
49. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Beider R et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504. (Pubitemid 38477774)
50. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase z of the a to z trial. JAMA 2004;292:1307-16. (Pubitemid 39223221)
51. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, CashinHemphill L, Hodis HN et al. Coronary angiographic changes with lovastatin therapy. The monitored atherosclerosis regression study (mars). Ann Intern Med 1993; 119:969-76. (Pubitemid 23334652)
52. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovem ME. Pravastatin limitation of atherosclerosis in the coronary arteries (plac i): Reduction in atherosclerosis progression and clinical events. Plac i investigation. J Am Coll Cardiol 1995;26:1133-9.
53. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The regression growth evaluation statin study (regress). Circulation 1995;91:2528-40.
54. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ 3rd, Jones PH, West MS et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study [leas]). Am J Cardiol 1997;80:278-86. (Pubitemid 27330142)
55. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ et al. Effects of monotherapy with an hmg-coa reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian coronary atherosclerosis intervention trial. Circulation 1994;89:959-68.
56. Effect of simvastatin on coronary atheroma: The multicentre antiatheroma study (MAAS). Lancet 1994;344:633-8.
57. Bestehorn HP, Reusing UF, Roskamm H, Betz P, Benesch L, Schemeitat K et al. The effect of simvastatin on progression of coronary artery disease. The multicenter coronary intervention study (CIS). European Heart Journal 1997;18:226-34. (Pubitemid 27107583)
58. Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W et al. Long-term effects of cholesterol lowering and angiotensinconverting enzyme inhibition on coronary atherosclerosis: The simvastatin/enalapril coronary atherosclerosis trial (scat). Circulation 2000;102:1748-54.
59. Peters RJ, Kok WE, Havenith MG, Rijsterborgh H, van der Wal AC, Visser CA. Histopathologic validation of intracoronary ultrasound imaging. J Am Soc Echocardiogr 1994;7:230-41.
60. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004;291:1071-80. (Pubitemid 38541684)
61. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The asteroid trial. JAMA 2006;295:155665.
62. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011;365:2078-87.
63. Schartl M, Bocksch W, Koschyk DH, Voelker W, Karsch KR, Kreuzer J et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001;104:387-92. (Pubitemid 32678266)
64. Kawasaki M, Sano K, Okubo M, Yokoyama H, Ito Y, Murata I et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol 2005;45:1946-53. (Pubitemid 40814113)
65. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The atherosclerosis risk in communities (aric) study, 1987-1993. Am J Epidemiol 1997;146:483-94. (Pubitemid 27391409)
66. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128:262-9. (Pubitemid 28090756)
67. O'Leary DH, Polak JF. Intima-media thickness: A tool for atherosclerosis imaging and event prediction. Am J Cardiol 2002;90:18L 21L.
68. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic carotid artery progression study (acaps) research group. Circulation 1994;90:1679-87. (Pubitemid 24320914)
69. Salonen R, Nyyssonen K, Porkkala E, Rummukainen J, Beider R, Park JS et al. Kuopio atherosclerosis prevention study (kaps). A population-based primary preventive trial of the effect of ldl lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995;92:1758-64.
70. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. Arbiter: Arterial biology for the investigation of the treatment effects of reducing cholesterol: A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106:2055-60. (Pubitemid 35192810)
71. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The meteor trial. JAMA 2007;297:1344-53. (Pubitemid 46513235)
72. Schmermund A, Achenbach S, Budde T, Buziashvili Y, Forster A, Friedrich G et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: A multicenter, randomized, doubleblind trial. Circulation 2006; 113:427-37. (Pubitemid 43803205)
73. Raggi P, Davidson M, Callister TQ, Welty FK, Bachmann GA, Hecht H et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond endorsed lipid lowering with ebt scanning (belles). Circulation 2005;112:56371.
74. Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin c, and vitamin e: The st. Francis heart study randomized clinical trial. J Am CoIl Cardiol 2005;46:166-72. (Pubitemid 40905146)
75. McEvoy JW, Blaha MJ, Defilippis AP, Budoff MJ, Nasir K, Blumenthal RS et al. Coronary artery calcium progression: An important clinical measurement? A review of published reports. J Am Coll Cardiol 2010;56:1613-22.
76. El Aidi H, Mani V, Weinshelbaum KB, Aguiar SH, Taniguchi H, Postley JE et al. Cross-sectional, prospective study of mri reproducibility in the assessment of plaque burden of the carotid arteries and aorta. Nature Clinical Practice 2009;6:219-28.
77. Migrino RQ, Bowers M, Harmann L, Prost R, LaDisa JF Jr. Carotid plaque regression following 6-month statin therapy assessed by 3t cardiovascular magnetic resonance: Comparison with ultrasound intima media thickness. J Cardiovasc Magn Reson 2011;13:37.
78. Vidal A, Bureau Y, Wade T, Spence JD, Rutt BK, Fenster A et al. Scan-rescan and intra-observer variability of magnetic resonance imaging of carotid atherosclerosis at 1.5 t and 3.0 t. Phys Med Biol 2008;53:6821-35.
79. Yuan C, Beach KW, Smith LH Jr, Hatsukami TS. Measurement of atherosclerotic carotid plaque size in vivo using high resolution magnetic resonance imaging. Circulation 1998;98:2666-71. (Pubitemid 28564000)
80. Corti R, Fayad ZA, Fuster V, Worthley SG, Helft G, Chesebro J et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: A longitudinal study by high-resolution, non-invasive magnetic resonance imaging. Circulation 2001;104:249-52. (Pubitemid 32666942)
81. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: Two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002;106:2884-7. (Pubitemid 35424736)
82. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Chaplin WF et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: A prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005;46:106-12. (Pubitemid 40905137)
83. Lee JM, Wiesmann F, Shirodaria C, Leeson P, Petersen SE, Francis JM et al. Early changes in arterial structure and function following statin initiation: Quantification by magnetic resonance imaging. Atherosclerosis 2008;197:951-8. (Pubitemid 351417906)
84. Kerwin WS, Liu F, Yarnykh V, Underhill H, Oikawa M, Yu W et al. Signal features of the atherosclerotic plaque at 3.0 tesla versus 1.5 tesla: Impact on automatic classification. J Magn Reson Imaging 2008;28:987-95.
85. Yarnykh VL, Terashima M, Hayes CE, Shimakawa A, Takaya N, Nguyen PK et al. Multicontrast black-blood mri of carotid arteries: Comparison between 1.5 and 3 tesla magnetic field strengths. J Magn Reson Imaging 2006;23:691-8.
86. Yuan C, Mitsumori LM, Ferguson MS, Polissar NL, Echelard D, Ortiz G et al. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. Circulation 2001;104:2051-6. (Pubitemid 33027045)
87. Underhill HR, Yuan C, Zhao XQ, Kraiss LW, Parker DL, Saam T et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: A high-resolution magnetic resonance imaging trial. Am Heart J 2008; 155:584 e581-588.
88. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 2001;103:926-33. (Pubitemid 32183796)
89. Cortellaro M, Cofrancesco E, Arbustini E, Rossi F, Negri A, Tremoli E et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: The atrocap study. Thromb Haemost 2002;88:41-7. (Pubitemid 34752265)
90. Reilly SD, Litovsky SH, Steinkampf MP, Caulfield JB. Statins improve human coronary atherosclerotic plaque morphology. Tex Heart Inst J 2008;35:99-103. (Pubitemid 351988635)
91. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (allhat-llt). JAMA 2002;288:2998-3007.
92. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (cards): Multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96. (Pubitemid 39140624)
93. Knopp RH, d"Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end-points in subjects with type 2 diabetes: The atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (aspen). Diabetes Care 2006;29:1478-85. (Pubitemid 44127567)
94. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T et al. Primary prevention of cardiovascular disease with pravastatin in japan (mega study): A prospective randomised controlled trial. Lancet 2006;368:1155-63. (Pubitemid 44444932)
95. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kuráta T, Sato H et al. Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The establish study. Circulation 2004;110:1061-8. (Pubitemid 39319003)